Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2013 Apr 4.
Published in final edited form as: Clin Neuropsychol. 2011 Feb;25(2):224–243. doi: 10.1080/13854046.2010.539577

Depression, Cognition, and Self-Appraisal of Functional Abilities in HIV: An Examination of Subjective Appraisal Versus Objective Performance

April D Thames 1, Brian W Becker 2, Thomas D Marcotte 3, Lindsay J Hines 1, Jessica M Foley 4, Amir Ramezani 1, Elyse J Singer 1, Steven A Castellon 1,2, Robert K Heaton 3, Charles H Hinkin 1,2
PMCID: PMC3616492  NIHMSID: NIHMS450254  PMID: 21331979

Abstract

Depression frequently co-occurs with HIV infection and can result in self-reported overestimates of cognitive deficits. Conversely, genuine cognitive dysfunction can lead to an under-appreciation of cognitive deficits. The degree to which depression and cognition influence self-report of capacity for instrumental activities of daily living (IADLs) requires further investigation. This study examined the effects of depression and cognitive deficits on self-appraisal of functional competence among 107 HIV-infected adults. As hypothesized, higher levels of depression were found among those who over-reported problems in medication management, driving, and cognition when compared to those who under-reported or provided accurate self-assessments. In contrast, genuine cognitive dysfunction was predictive of under-reporting of functional deficits. Together, these results suggest that over-reliance on self-reported functional status poses risk for error when diagnoses require documentation of both cognitive impairment and associated functional disability in everyday life.

Keywords: Depression, Self-report, Functional ability, Cognition, HIV

INTRODUCTION

HIV-associated cognitive impairments include deficits in attention/working-memory, information processing, learning and memory, and executive function (Woods, Moore, Weber, & Grant, 2009). Consequently, cognitive impairment can interfere with the capacity to perform instrumental activities of daily living (IADLs). IADL impairments among HIV-infected individuals have been repeatedly documented in the areas of medication adherence, driving, employment, finance management, cooking, and shopping (Heaton, Marcotte, et al., 2004; Hinkin et al., 2002; Marcotte et al., 1999). While performance-based measures of cognition are increasingly used to assess neuropsychological dysfunction, self-reported measurements continue to dominate assessment of IADL status, particularly in the early stages of HIV infection when identifying the degree of functional impairment can be unclear (Bassel, Rourke, Halman, & Smith, 2002; Carter, Rourke, Murji, Shorre, & Rourke, 2003).

Inconsistencies between subjective cognitive complaints and actual impairment of neuropsychological (NP) performance have been well documented and thus call into question the reliability of self-reported cognitive deficits (Hinkin et al., 1996; van Gorp et al., 1991; Wilkins et al., 1991). This is particularly disconcerting given the heavy reliance on self-report for diagnosing HIV-Associated Neurocognitive Disorders (HAND; Antinori et al., 2007) and for assessing the presence of IADL impairments more generally, particularly in the HIV+ population. In particular, the use of instruments that utilize caregiver reports have been studied more thoroughly in the geriatric dementia population (e.g., Cummings et al., 1994; Okura et al., 2010). Factors influencing self-reported IADLs have not been as thoroughly studied in the HIV literature despite the serious consequences that can result from IADL decrements. For example, suboptimal adherence to HIV medications can lead to increased viral replication (Perno et al., 2002), emergence of treatment resistant viral strains (Harrigan et al., 2005) and, ultimately, heightened risk of death (Lima et al., 2007). In a similar manner, failure to recognize or appreciate driving impairments can result in serious patient or public safety risks by increasing the likelihood of on-road accidents (Marcotte et al., 2006).

Hence, there is a pressing need to identify factors that influence the accuracy of self-reported functional abilities. Among various neurological populations, depression and lack of awareness of one’s deficits have been shown to differentially impact self-reported cognitive complaints and thus contribute to discrepancies with observed NP performance (Antoine, Antoine, Guermonprez, & Frigard, 2004; Hoth et al., 2007; Smith, Henderson, McCleary, Murdock, & Buckwalter, 2000; Starkstein, Sabe, Chemerinski, Jason, & Leiguarda, 1996). Of interest to this study was whether depression and cognitive impairment lead to discrepancies between self-reported versus performance-based assessment of functional abilities in the areas of medication management and driving.

HIV and depression

HIV-infected (HIV+) individuals demonstrate higher rates of depression than the general population (Basu, Chwastia, & Douglas, 2005; Ciesla & Roberts, 2001; Rabkin et al., 1997; Satz et al., 1997). Surprisingly, although depression has been linked to greater NP deficits in a wide range of disorders (see reviews by Burt, Zembar, & Niederehe, 1995; Cassens, Wolf, & Zola, 1991), it does not appear to be associated with increased NP impairment in HIV (Cysique et al., 2007; Goggin et al., 1997; Grant et al., 1993; Hinkin et al., 1992; Mapou et al., 1993; Mason et al., 1998; Millikin, Rourke, Halman, & Power, 2003; von Giesen, Baecker, Hefter, & Arendt, 2001). Nevertheless, depression in HIV+ individuals is frequently associated with increased cognitive complaints (Carter et al., 2003; Cysique et al., 2007; Hinkin et al., 1996; Hinkin, Castellon, Van Gorp, & Satz, 1998; Rourke, Halman, Mark et al., 1999; Sadek, Vigil, Grant, Heaton, & HNRC Group, 2007). In general, patients with depression often demonstrate cognitive distortions about their own abilities, and this phenomenon may explain why depressed individuals tend to overestimate disability in their daily functioning (Ammassari et al., 2004; Haubrich et al., 1999; Paterson et al., 2000; Ragland, Satariano, & MacLeod, 2005; Windsor, Anstey, Butterworth, Luszcz, & Andrews, 2007).

HIV, cognition, and deficit awareness

Depressed mood, however, is not the only factor associated with compromised self-report. Individuals with formally documented neurocognitive impairment tend to report lower levels of depression and under-report their cognitive difficulties (Hinkin et al., 1996; Rourke, Halman, & Bassel, 1999; van Gorp et al., 1991). These types of reporting errors are particularly likely to occur with patients having impairments in abilities presumed to be mediated by frontal executive systems, thus supporting a neurological basis for lack of awareness (Rosen et al., 2009; Snowden, Neary, & Mann, 2002).

Also among HIV+ samples, discrepancies between self-reported and objective measures of medication adherence (e.g., electronic monitoring devices) have also been observed. Results comparing these two methods have shown that self-reported adherence rates are consistently higher (ranging from 18 to 34 percentage points) than adherence rates obtained through electronic monitoring recordings of real-world medication adherence (for review see Simoni, Frick, & Huang, 2006). Few studies have looked at factors associated with discrepancies between self-report and electronic monitoring of medication adherence. However, one preliminary study conducted by our group found that discrepancies between electronic monitoring and self-report estimates were associated with lower cognitive functioning and externalized locus of control (Levine et al., 2006).

Inconsistencies between self-reported and objective functional performance have already been documented among patients who have progressed from Mild Cognitive Impairment (MCI) to Alzheimer’s disease (AD) (Albert, Tabert, Dienstag, Pelton, & Devanand, 2002; Roberts, Clare, & Woods, 2009). In a study by Okonkwo and colleagues (2009), individuals with MCI overestimated their financial and driving abilities, suggesting that diminished awareness may be a marker of increasing cognitive decline.

Performance-based methods for assessing functional abilities in HIV have included the Medication Management Task (MMT; Albert et al., 1999; Heaton et al., 2004) and PC-based driving simulation tasks (Marcotte et al., 1999, 2004, 2006). These functional assessment methods are gaining popularity in the HIV literature, since they have been shown to be more reliable and objective measures of “real-world” performance (Heaton et al., 2004; Marcotte et al., 1999). The MMT measures the ability to manage medications by performing laboratory tasks requiring responses to questions related to refill, instructions on when and how to take the medications, and dosage based on pill bottle label instructions. Driving simulators provide an opportunity to safely place individuals into both common and emergency driving situations and to approximate and evaluate real-world driving behaviors (Marcotte et al., 2004).

To our knowledge, there are no studies examining psychiatric and cognitive factors contributing to discrepancies between self-report versus objective measures of everyday functional abilities in HIV-infected samples. However, we expect that depression and cognition will differentially influence self-reported functional abilities in the areas of medication management and driving capacity in a fashion similar to that observed for cognitive complaints and neuropsychological performance.

The purpose of the current study was to examine whether depression and cognitive dysfunction influenced discrepancies between self-reported and objective IADL functioning among HIV-infected adults. Although not a primary study aim, we also examined whether depression accounted for discrepancies between self-reported and current neuropsychological functioning. We predicted that (1) Higher levels of depression would be found among those who consistently over-report impairments in medication adherence, driving, and neuropsychological functioning compared to those who consistently under-report or provide accurate self assessments; (2) Impaired cognition would be found among those who under-report impairments in medication management and driving when compared to over-reporters and those who accurately report impairments; (3) Depression and cognitive impairments associated with frontal systems functioning (i.e., attention/working memory, information processing speed, and executive functions) would most accurately classify self-reported assessment groups.

METHOD

Participants

Participants included 107 HIV+ adults who were recruited from community agencies and medical centers within the Los Angeles area. Individuals presenting with a history of psychosis within the past year or alcohol/illicit substance abuse or dependence within the last month were excluded based on results of data collected using the Structured Clinical Interview for DSM-IV, Axis I Disorders (SCID; First, Spitzer, Gibbon, & Williams, 1995). Participants were also excluded if they presented with history of traumatic brain injury with loss of consciousness greater than 30 minutes, or with medical comorbidities apart from HIV that are believed to affect cognitive function (e.g., brain anoxia, kidney dysfunction, CNS opportunistic infections, seizures, or hepatitis C virus). Individuals presenting with known cerebrovascular events (e.g., strokes) were also excluded. Please see Table 1 for demographics and characteristics of the entire sample.

Table 1.

Demographic characteristics of the whole sample (N=107)

Variable
Age   49.1 (11.1)
Education   13.7 (2.2)
% Male     81%
Ethnicity
    Caucasian   33.6%
    African American   47.7%
    Hispanic   13.1%
    Asian American     2.0%
    Native     2.0%
    Other     2.0%
*Recent Cluster of Differentiation 4 (CD4) 420.0 (400.25)
*Nadir CD4 150.0 (227.3)
%Undetectable viral load     63%
%Independently manage medications     95%
%Meets Acquired Immune Deficiency Syndrome     80%
(AIDS) Criteria
Number of years infected   13.05 (6.1)
Beck Depression Inventory (BDI)-II total score   11.9 (9.3)
Medication Management Task total score   13.9 (3.7)
Driving errors total score     2.4 (1.3)
Neuropsychological T-score   42.8 (6.7)
**% cognitively impaired   47.3%
*

Median and Interquartile Range.

(based on opportunistic infection (OI) or CD4 < 200).

**

(Global Deficit Score >0.5).

Procedure

Participants were administered the Beck Depression Inventory, Second Edition (BDI-II; Beck, 1987) to assess current level of depression, the Patient Assessment of Own Functioning Inventory (PAOFI; Chelune, Heaton, & Lehman, 1986) to assess perceived cognitive decline since illness onset, the Medication Management Task-Revised (Heaton, Marcotte et al., 2004) to assess both self-reported medication management and performance-based capacity for accurate medication management, a driving history questionnaire to assess perceived decline in a driving ability since illness onset, and a laboratory computer-based driving simulator to approximate actual driving ability.

Self-reported cognitive status

Participants were then classified into self-reported cognitive status groups (reported decline n = 58; reported no decline n = 39) based on their response (i.e., Yes/No) to item #34 from the Patient Assessment of Functioning Inventory (PAOFI; Chelune et al., 1986) assessing whether they perceived a decline in cognitive functioning since the onset of illness. Ten participants responded “Don’t know” to this question and therefore were not included in the discrepancy analysis. In addition, PAOFI total score was used to examine the degree of association between self-reported cognitive functioning, depression, and neuropsychological performance (see Table 2).

Table 2.

Neuropsychological battery

Domain Test name Variable used Normative data (citation)
Language Controlled Oral Word Association Test FAS/Animals Heaton, Miller et al., 2004
Boston Naming Test Total Score Heaton, Miller et al., 2004
Executive functioning Trail Making Test Part B Heaton, Miller et al., 2004
Wisconsin Card Sorting Test Perseverative Errors Heaton et al., 1993
Stroop Color and Word Test Interference Golden, 1978
Information processing speed Trail Making Test Part A Heaton, Miller et al., 2004
Wechsler’s Adult Intelligence Scale-III (WAIS-III) Digit Symbol Coding Taylor & Heaton, 2001
(WAIS-III) Symbol Search Taylor & Heaton, 2001
Conners’ Continuous Performance Test-2 (CPT-II) Reaction Time Conners and MHS Staff, 2000
Attention and working memory Paced Auditory Serial Addition Test (PASAT) Total Score Dieher et al., 2003
CPT-II Omissions and Comissions Conners and MHS Staff, 2000
WAIS-III Letter–Number Sequencing Taylor & Heaton, 2001
Learning and memory Hopkins Verbal Learning Test – Revised (HVLT-R) Total Learning Score and Recall Brant & Benedict, 2001
Brief Visual Memory Test – Revised (BVMT-R) Total Learning Score and Recall Benedict, 1997
Visuospatial functioning WAIS-III Block Design Taylor & Heaton, 2001
Motor functioning Grooved Pegboard Dominant and Non-Dominant Hand Score Heaton, Miller et al., 2004

Neuropsychological performance

All participants completed a comprehensive neuropsychological test battery administered by trained psychometrists who were supervised by a board certified neuropsychologist (CHH). (See Table 2 for a list of neuropsychological tests.) Test scores were converted to demographically corrected T-scores (with a mean of 50 and a standard deviation of 10) using published normative data (see Table 2) and grouped by neurocognitive domain. Deficit scores were then calculated using an algorithm developed by Heaton and colleagues (Heaton, Miller et al., 2004) that assigns an impairment rating to T scores as follows: T > 39 = 0; 39 ≥ T ≥ 35 = 1; 34 ≥ T ≥ 30 = 2; 29 ≥ T ≥ 25 = 3; 24 ≥ T ≥ 20 = 4; T < 20 = 5. Deficit scores for each neuropsychological test were then averaged into one score to reflect global impairment (GDS). Individuals were classified as either cognitively unimpaired or impaired based on a deficit score cutoff of 0.5 for impairment. The global deficit score approach has been demonstrated as having good predictive validity for detecting cognitive impairments in HIV-infected individuals (Carey et al., 2004). Groups typifying each reporting style were created by comparing participants’ self-report (i.e., decline vs no cognitive decline) to objective neuropsychological impairment classification (i.e., impaired versus unimpaired based on GDS) yielding the following groups: Accurate self-assessors (n = 41) who can be further subdivided as either unimpaired and reported no decline (n = 25) or impaired and reported decline (n = 16); Over-reporters (unimpaired but reported decline, n = 27); and Under-reporters (impaired but reported no decline, n = 35).

MEDICATION MANAGEMENT ASSESSMENT

Medication Management Task – Revised

Participants were administered the Columbia Medication Management Task – Revised (Heaton, Marcotte et al., 2004), in which they were asked to perform tasks and respond to questions about five different medications based on pill bottle labels, the number of pills in each bottle, and directions on package inserts. Self-reported medication management was based on participants’ responses to questions from the MMT-R that assessed whether they perceived a decline in their ability to manage medications. A majority of our participants (n = 99) reported no problems in managing their medications, whereas a small number (n = 8) of participants either reported difficulty with managing their medications or that they received assistance with medication management.

The performance segment of the MMT-R required participants to determine information such as when a refill is needed, which medications need to be taken with food, how many pills are required to take the correct dosage, and how to correctly place pills in a pill box based on the instructions listed on the labels. Participants’ total points (out of a maximum of 17) earned on the MMT-R task were used as the outcome variable to reflect overall performance. A cutoff score of 11, which corresponded to 1 standard deviation below the average score (M = 13.69) for cognitively normal participants, was used to classify good (n = 82) versus bad (n = 24) performance. MMT-R performance data were missing for one of our participants. Reporting groups were created based on self-reported versus observed difficulties in medication management: Accurate self-assessors n = 72: self-reported no medication management problems/performed normal on MMT-R (n = 71), self-reported medication management problems/performed poorly on MMT-R (n = 1); Over-reporters n = 7; Under-reporters n = 26. In addition to examining self-report of medication management, self-reported medication adherence was assessed to capture information about perceived medication-taking behaviors more generally. Self-reported medication adherence was gathered from the AIDS Clinical Trial Group (ACTG) questionnaire, which provides data regarding percentage of self-reported antiretroviral medication doses taken over the last 30 days. Percent adherence was calculated by subtracting the number of reported missed doses within the last 30 days from the total number of doses prescribed, dividing this number by the total number of doses prescribed, and multiplying it by 100. Based on a frequently used criterion in the literature (Simoni et al., 2006), a cutoff of 95% was used to classify participants into good adherers (n = 72) versus poor adherers (n = 31). Adherence data were missing for four participants.

Discrepancies between self-reported medication adherence and performance on MMT-R were also evaluated. Discrepancy groups were created based on self-reported adherence versus observed difficulties in medication management: consistent (i.e., self-report matched MMT-R performance) n = 69: negative discrepancy (i.e., self-reported suboptimal adherence, performed normally on MMT) n = 16; positive discrepancy (i.e., self-reported optimal adherence, but performed poorly on MMT) n = 17.

Self-reported driving ability

Participants were classified into self-reported driving impairment groups (reported decline n = 66; reported no decline n = 25) based on their response (i.e., Yes/No) to an item from a driving history questionnaire assessing whether they perceived a decline in driving ability since the onset of illness. Five participants were unable to respond to this question because they did not drive prior to illness onset and were therefore excluded from the driving discrepancy analysis.

Driving performance

Participants completed a laboratory-based driving simulator task (STISIM driving version 2.0 software; Rosenthal, Parseghian, Allen, & Stein, 1995; Systems Technology, Inc, Hawthorne, CA). For this simulation participants completed the second phase, the Routine and Emergency Driving task, which is designed to simulate city–country driving (Marcotte et al., 1999). During this phase participants must pass cars, stop at traffic lights, follow curving roads, drive around stalled automobiles, and avoid potential accidents (e.g., a pedestrian stepping onto the road, a car in front slamming on its brakes). Data regarding speed and accidents were collected by the software program and employed as outcome variables.

Driving performance was evaluated using a composite error score that included the number of: (a) off-road accidents, (b) speeding tickets, (c) collisions, and (d) pedestrian hits recorded during the simulation. Based on a cutoff score (3.4) that represented one standard deviation below the average performance (M = 2.2) for our internal sample of cognitively normal participants, participants were classified as either good drivers (n = 67) or poor drivers (n = 19). The driving simulator task was discontinued for five participants due to difficulties following task instructions. Reporting groups were then created based on self-reported versus observed driving performance: Accurate self-assessors n = 50: self-reported no driving impairments/performed normal on driving simulator (n = 49); reported driving impairments/performed poorly on driving simulator (n = 1); Over-reporters n = 23; Under-reporters n = 13.

Statistical analyses

The false discovery rate (FDR) approach was used to correct for multiple comparisons (see Benjamini & Hochberg, 2000 for review). Instead of controlling for the chance of any false positives (e.g., Bonferroni method), FDR controls for the expected proportion of false positives within a total number of comparisons.

The adjusted alpha level to correct for 25 comparisons using p = .05 in our calculation was .036. Hence, all p-values below .036 were considered statistically significant. Preliminary analyses revealed no significant demographic group differences between functional discrepancy groups (see Table 2). However, there were demographic associations with study variables; age was negatively correlated with MMT-R performance, r(106) = −.192, p = .04, whereas estimated duration of HIV infection was positively associated with MMT-R performance, r(106) = .242, p = .01.

Distributions of Medication Management Task (MMT) total scores, medication adherence rates, driving errors, and global neuropsychological T-scores were evaluated for normality, skewness, and kurtosis. All variables were normally distributed according to these statistics. For discriminant analyses, assumptions pertaining to linearity, multivariate normality, and equal population covariance among predictor groups were verified and met.

Primary study statistical procedures were as follows: (1) ANOVA was used to examine depression among self-reported driving, medication, and cognitive impairment groups; (2) Partial correlations were used to examine the relationships between depression scores, cognition, and performance on the MMT-R and Driving Simulator; (3) Cross tabulations were used to identify which participants consistently under-reported, over-reported, or were accurate in their self-assessments in at least two out of the three functional measures (i.e., cognition, medication management, and driving); (4) Participants were recoded into groups of consistent Accurate self assessors n = 56, Over-reporters n = 22, and Under-reporters n = 12. (Note: We were unable to classify seven of our participants due to inconsistent responding across the three functional measures, and due to the small number of participants whose self-reports of functional impairments were confirmed by functional performance measures, we were unable to split accurate self-reporters into impaired versus unimpaired.) (5) Discriminant function analysis was then used to determine the independent predictive value of depression and cognition status on self-report consistency groups

RESULTS

Depression, cognition and self-reported functional capacity vs functional performance self-reported driving ability

Participants who self-reported a decline in driving ability demonstrated higher levels of depression than those who reported no decline, F(1, 89) = 13.56; MSE = 75.74, p < .001, ηp2 = 0.13. Self-reported driving groups did not differ in global neuropsychological functioning (p > .05).

Self-reported driving vs driving performance

Surprisingly, participants who reported no decline in driving ability exhibited a greater number of errors on the driving simulator task when compared to participants who reported decline, F(1, 84) = 4.75, MSE = 1.63, p = .03, ηp2 = 0.05. Those who over-reported problems in driving (i.e., those who complained of difficulties that were not objectively verified) demonstrated higher depression scores than those who under-reported problems or were accurate in their self-assessments, F(2, 83) = 4.29, MSE = 81.15, p = .01, ηp2 = 0.09. Contrary to expectation, reporting groups (i.e., Accurate self-assessors, Over-reporters and Under-reporters) did not significantly differ in neuropsychological functioning (p > .05).

Self-reported medication management

Participants who reported problems managing their medications demonstrated higher levels of depression than those who did not report problems, F(1, 105) = 6.65, MSE = 82.49, p = .01, ηp2 = 0.05. However, participants who complained of medication management difficulties in their everyday lives did not differ in MMT-R performance from participants who denied experiencing medication management difficulties or in global neuropsychological functioning (p > .05).

Participants who over-reported deficits in medication management demonstrated the highest levels of depression when compared to under-reporters or accurate self-assessors, F(2, 103) = 4.46, MSE = 86.15, p = .01; ηp2 = 0.07. Under-reporters performed more poorly on measures of neuropsychological functioning than over-reporters and accurate self-assessors, F(2, 103) = 26.92, MSE = 31.73, p < .001, ηp2 = 0.31.

We recognize that our statistical analyses with regard to self-reported medication management is limited due to the small number (n = 8) of participants who reported problems. Nevertheless, inspection of group BDI-II scores revealed a dramatic difference between self-report groups, with higher scores among those who reported problems (M = 23.25 vsM = 11.63). Furthermore, higher depression scores were found among participants who over-reported deficits in medication management.

Self-reported medication adherence

To expand on the analysis above, we also examined the difference between self-reported medication adherence and objective performance on the MMT-R. Although it can be argued that these variables reflect distinct constructs, their similarity lies in the assessment of behaviors that are involved in accurately self-administering medications. Interestingly, we found similar results in that participants who reported poor adherence to their medication regimen exhibited higher levels of depression than participants who reported good adherence, F(1, 101) = 10.33, MSE = 80.10, p = .002, ηp2 = 0.08. It is possible that depression resulted in poor adherence rates for these participants; nevertheless, adherence groups did not differ in MMT performance or global neuropsychological functioning (p > .05).

Depression and cognitive complaints versus objective cognitive performance

Self-reported cognition

Participants who reported declines in cognition were significantly more depressed than those who reported no decline, F(1, 95) = 17.03, MSE = 66.17, p < .001; ηp2 = 0.14.

Self-report cognition vs neuropsychological performance

As expected, over-reporters (i.e., participants who complained of cognitive deficits that were not demonstrated on objective neuropsychological testing) exhibited higher levels of depression than under-reporters and accurate self-assessors, F(2, 100) = 5.68, MSE = 70.42; p = .01, ηp2 = 0.10. However, under-reporters did not significantly differ in neuropsychological performance from accurate assessors who self-reported cognitive deficits. See Table 3 for means and standard deviations.

Table 3.

Characteristics of functional discrepancy groups

Variable Disability
Over-reporters
(n = 22)
Disability
Under-reporters
(n = 12)
Accurate
(n = 56)
**Results
Age   49.5 (5.5)   52.7 (9.4)   50.9 (10.7) Not Significant
Education   13.8 (3.0)   12.7 (1.4)   13.7 (2.2) Not Significant
Male (%)   85%   81%   82% Not Significant
Ethnicity
    Caucasian   29%   30%   38% Not Significant
    African American   57%   60%   41% Not Significant
    Hispanic   14%     9%   13% Not Significant
    Asian American     0     0     3% Not Significant
    Native     0     0     3% Not Significant
    Other     0     1%     2% Not Significant
*Cluster Differentiation 4 (CD4) 369.0 (376) 440.0 (371) 440.0 (377) Not Significant
*Nadir CD4 197.0 (173.5) 150.0 (180) 143.5 (275.2) Not Significant
% Undetectable viral load   78%   75%   77% Not Significant
% Meets Acquired Immune Deficiency   95%   91%   86% Not Significant
Syndrome (AIDS) Criteria
# Years infected   13.14 (7.3)   12.1 (8.4)   13.2 (6.1) Not Significant
% Independently manage medications   79% 100%   97% Not Significant
**Beck Depression Inventory -II   19.6 (10.9)     9.0 (9.7)     9.6 (7.5) a > b,c
**Medication Management Task total   15.0 (2.8)     8.0 (3.5)   14.4 (3.1) b < a,c
**Driving Errors     2.1 (1.6)     4.0 (1.7)     2.2 (1.4) b > a,c
**Global Neuropsychological T-score   46.7 (5.0)   35.7 (6.0)   44.2 (5.8) b < a,c
**Attention T-score   46.7 (10.3)   36.1 (18.3)   42.4 (9.1) b < a,c
**Processing Speed T-score   45.5 (8.7)   38.6 (10.0)   46.8 (8.9) b < a,c
**Learning and Memory T-score   45.1 (7.58)   28.8 (9.2)   41.3 (10.9) b < a,c
**Executive T-score   50.0 (6.6)   37.4 (8.6)   47.8 (7.4) b < a,c
**Motor T-score   49.0 (7.3)   39.4 (8.9)   45.1 (8.2) b < a,c
**Verbal T-score   52.6 (7.8)   43.5 (9.4)   47.5 (8.5) b < a,c
**††Patient Assessment of Functioning   12.3 (7.2)     7.2 (6.8)     6.15 (5.5) a > b,c
(PAOF) total score
**% cognitively impaired   14% 100%     38% b > a,c
(Global Deficit Sscore > 0.5)
*

Median and interquartile range.

Based on opportunistic infection (OI) or CD4 < 200.

††

Higher scores represent more cognitive complaints.

**

p < .036; a = over-reporters; b = under-reporters; c = accurate self-assessors.

Depression, neuropsychological functioning, and performance on functional tasks

Despite depression being a powerful predictor of subjective complaints of functional decline, current level of depression was not significantly associated with objective performance on the MMT-R, r(106) = .171; p = .15, driving simulator performances, r(86) = −.081, p = .52, or measures of global neuropsychological functioning, r(107) = −.022, p = .82. However, neuropsychological functioning was significantly associated with total MMT-R score, r(106) = .617, p < .001, and number of errors produced on the driving simulator, r(86) = −.219, p = .024.

Predictors of overall self-report/performance discrepancies

For participants who consistently over-reported (n = 22) or under-reported (n = 12) functional impairments in medication management and driving, One-way ANOVA revealed differences in current depression, F(1, 32) = 6.01; p = .003; ηp2 = 0.12, and neuropsychological performance in domains of attention, F(1, 32) = 3.87; p = .025; ηp2 = 0.08, information processing speed, F(1, 32) = 4.23, p = .01; ηp2 = .09, language, F(1, 32) = 8.77, p = .006; ηp2 = 0.21, learning and memory, F(1, 32) = 30.34, p < .0001; ηp2 = 0.17, executive functioning, F (1, 32) = 9.50, p < .0001; ηp2 = 0.18, and motor functioning, F(1, 32) = 11.25; p < .0001; ηp2 = 0.20. As expected, under-reporters of functional deficits performed significantly more poorly across the aforementioned cognitive domains, whereas over-reporters demonstrated higher levels of current depression. See Table 3 for means and standard deviations.

Depressive symptoms, cognition, and discrepancy classification

The next series of analyses examined the differential predictive value of depression and cognition on self-reporting style among the subset of participants who consistently over-reported or under-reported functional deficits in medication management and driving. Discriminant Function Analysis using the leave-one-out (LOO) jackknife classification approach (see Huberty, 1994, for review) revealed that depression and the cognitive domains of attention, information processing speed, learning and memory, verbal functioning, motor functioning, and executive functioning were significant predictors of reporting style (i.e., over-reporters, under-reporters) (λ = 0.40, χ2 = 25.47, p < .001, ηp2 = 0.59). The classification results show that the model correctly predicted 85.7% of over-reporters and 78.9% of under-reporters, with an overall classification rate of 81.8%.

DISCUSSION

The current study expands on findings in the self-appraisal literature by addressing the ways in which depression and cognition influence and mediate self-reported IADL functioning (i.e., medication management and driving), and whether objective measurements confirm these self-reports in an HIV-infected sample.

Our results demonstrate that individuals with depressive symptoms tend to inaccurately over-report cognitive and functional impairments. Specifically, those who over-reported cognitive and functional deficits demonstrated the highest levels of depression relative to other appraisal groups. Alternatively, individuals who under-reported deficits in cognitive and functional abilities reported the lowest levels of depression. Although neurocognitive functioning was strongly related to performance on driving and medication management, depression was not, suggesting that poor performance on laboratory-based measures of functional abilities are more sensitive to cognitive deficits than mood status. As previously discussed, we were unable to subdivide accurate self-reporters into functionally unimpaired and impaired groups due to the small cell sizes of participants whose self-reported functional impairments were confirmed by functional performance; that is, a majority of accurate self-reporters demonstrated normal functional performance. Because we were unable to make comparisons between under-reporters and participants who accurately reported impairments, it was not possible to establish whether poor cognition results in a “true” lack of awareness of functional deficits in medication management and driving.

Nonetheless, we examined differences in cognitive functioning between participants who consistently under-reported, over-reported, and were accurate in their self-assessments of functional abilities (i.e., medication management and driving). We found that under-reporters were more cognitively impaired than over-reporters and accurate self-assessors, suggesting that cognitive impairment may play an even greater role in self-report of functional abilities. Our findings related to depression were consistent across all analyses, thereby indicating that depressive symptoms are more likely to lead to inaccurate self-report of functional deficits than neuropsychological functioning. Moreover, our participants were not formally diagnosed with depression; rather they presented with a range of depressive symptoms. This suggests that a clinical diagnosis of depression is not necessary for overestimations of functional disability to occur. As a whole, our sample of participants demonstrated normal to mildly impaired levels of cognitive functioning. It remains possible that only at greater levels of cognitive impairment does diminished awareness of functional deficits become more apparent, which is consistent with findings from Marcotte and colleagues (2004) demonstrating that a subset of HIV+ drivers who failed the on-road driving simulator were unaware of their poor performance.

This study found that depressive symptoms, learning and memory, attention/working memory, information processing speed, language, motor functioning, and executive functioning most accurately classified over-reporters and under-reporters, which is consistent with previous studies that have linked these domains to impaired awareness suggesting dysfunctions in frontal circuitry, as well as HIV-associated cognitive impairment. This finding highlights the importance of these cognitive and psychiatric variables when predicting the ability to provide accurate self-report of functional abilities.

Consistent with expectations, there were no significant relationships between self-reported functional abilities and objective functional task performance. Considering the previous findings, it is plausible that psychiatric factors and cognition may account for the lack of relationship in self-appraisal and awareness of functional abilities. Our findings are in accordance with previous studies linking discrepancies between subjective ratings versus objective neuropsychological performance with depression among individuals with HIV (Carter et al., 2003; Heaton, Marcotte et al., 2004; Hinkin et al., 1996; Moore et al., 1997; van Gorp et al., 1991).

We recognize that laboratory-based measures of functional capacity may not fully represent actual functional abilities, so the extent to which we can make inferences about functional capacity is limited. Future investigations comparing performance on functional measures to real-world performance (e.g., comparing simulated driving performance to on-road driving, such as was done by Marcotte et al., 2004) would help to clarify the accuracy of performance-based functional measures. Although we did not have access to informant ratings in this study, comparing informant ratings to functional performance would also help to address the predictive value of these functional measures.

Despite these limitations, several interesting results from the current study have implications for working with individuals infected with HIV. First, our findings suggest that the neurocognitive and psychiatric aspects of HIV/AIDS are largely independent of one another (Grant et al., 1993; Hinkin et al., 1992; Mapou et al., 1993; Mason et al., 1998; von Giesen et al., 2001). As such, cognitive complaints or self-reported functional ability may not be accurate assessments of true performance. Rather, functional complaints may indicate mood disturbances, such as anhedonia, that could interfere with everyday functioning independently of functional ability.

Under-reporters constituted approximately 13% of participants who were consistent in self-reporting style. Not only is this concerning in the context of patient welfare, but also patient unawareness may be misinterpreted by the clinician as a “stable” or “improved” level of functioning. Inaccuracies in self-report highlight the importance of integrating objective laboratory based measures of functional abilities in clinical assessments of individuals with illnesses, such as HIV, that often co-occur with depression (Castellon et al., 2006). Clinically, this is important when evaluating functional decline, as over-reliance on self-report may lead to inaccurate diagnostic conclusions.

The ability to function independently is an important consideration when determining a diagnosis of HIV-associated Neurocognitive Disorder (HAND; Antinori et al., 2007). As outlined in the HAND nosology, in order to diagnose HIV-associated mild neurocognitive disorder, cognitive impairment must produce mild interference with daily functioning. This may be established using performance-based measures based functional measures such as those in the current study, as well as by patient self-report or observation by others. As demonstrated by this study and others, relying on self-report among depressed individuals can lead high rates of false positives.

In sum, our findings underscore the importance of considering depression and cognitive ability when assessing self-reports of functional status among individuals with HIV. More importantly, findings from our study suggest that using objective IADL measures such as the Medication Management Task may more accurately detect declines in functional ability than self-report. Just as over-reliance on subjective self-report of cognitive status can lead to diagnostic error, over-reliance on patients’ self-reported claims of functional decline, or lack thereof, should be avoided.

ACKNOWLEDGMENTS

This study was funded by the VA merit review award entitled: Aging in HIV/AIDS: Neurocognitive Sequelae and Functional Consequences (PI: Charles Hinkin, Ph.D.). Special thanks to members of our laboratory Jiah Jang, Michelle Kim, Melissa Choi, Gabriel Waterman, Laurie Chew, and Arielle Newman who assisted with participant recruitment and data collection.

Footnotes

Full terms and conditions of use: http://www.tandfonline.com/page/terms-and-conditions

Publisher's Disclaimer: This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

REFERENCES

  1. Albert SM, Tabert MH, Dienstag A, Pelton G, Devanand D. The impact of mild cognitive impairment on functional abilities in the elderly. Current Psychiatry Report. 2002;4(1):64–68. doi: 10.1007/s11920-002-0015-8. [DOI] [PubMed] [Google Scholar]
  2. Albert SM, Weber CM, Todak G, Polanco C, Clouse R, McElhiney M, et al. An observed performance test of medication management ability in HIV: Relation to neuropsychological status and medication outcomes. AIDS and Behavior. 1999;3:121–128. [Google Scholar]
  3. Ammassari A, Antinori A, Aloisi MS, Trotta MP, Murri R, Bartoli L, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004;45(5):394–402. doi: 10.1176/appi.psy.45.5.394. [DOI] [PubMed] [Google Scholar]
  4. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd D, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–1799. doi: 10.1212/01.WNL.0000287431.88658.8b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Antoine C, Antoine P, Guermonprez P, Frigard B. Awareness of deficits and anosognosia in Alzheimer2019;s disease. Encephale. 2004;30(6):570–577. doi: 10.1016/s0013-7006(04)95472-3. [DOI] [PubMed] [Google Scholar]
  6. Balas M, Balash Y, Giladi N, Gurevich T. Cognition in multiple system atrophy: Neuropsychological profile and interaction with mood. Journal of Neural Transmission. 2010;117(3):369–375. doi: 10.1007/s00702-009-0365-z. [DOI] [PubMed] [Google Scholar]
  7. Bassel C, Rourke SB, Halman MH, Smith ML. Working memory performance predicts subjective cognitive complaints in HIV infection. Neuropsychology. 2002;16(3):400–410. doi: 10.1037//0894-4105.16.3.400. [DOI] [PubMed] [Google Scholar]
  8. Basu S, Chwastia L, Douglas B. Clinical management of depression and anxiety in HIV-infected adults. AIDS. 2005;19:2057–2067. doi: 10.1097/01.aids.0000182518.84407.32. [DOI] [PubMed] [Google Scholar]
  9. Beck AT. Beck Depression Inventory: Manual. San Antonio, TX: Psychological Corporation; 1987. [Google Scholar]
  10. Benedict RHB. Brief Visuospatial Memory Test – Revised. Lutz, FL: Psychological Assessment Resources, Inc.; 1997. [Google Scholar]
  11. Benjamini Y, Hochberg Y. The adaptive control of the false discovery rate in multiple comparison problems. Journal of Education and Behavioral Statistics. 2000;25(1):60–83. [Google Scholar]
  12. Brandt J, Benedict RH. Hopkins Verbal Learning Test – Revised. Lutz, FL: Psychological Assessment Resources, Inc.; 2001. [Google Scholar]
  13. Burt DB, Zembar MJ, Niederehe G. Depression and memory impairment: A meta-analysis of the association, its pattern, and specificity. Psychological Bulletin. 1995;117:285–305. doi: 10.1037/0033-2909.117.2.285. [DOI] [PubMed] [Google Scholar]
  14. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. Journal of Clinical Neuropsychology. 2004;26:307–319. doi: 10.1080/13803390490510031. [DOI] [PubMed] [Google Scholar]
  15. Carter SL, Rourke SB, Murji S, Shorre D, Rourke BP. Cognitive complaints, depression, medical symptoms, and their association with neuropsychological functioning in HIV infection: A structural equation model analysis. Neuropsychology. 2003;17(3):410–419. doi: 10.1037/0894-4105.17.3.410. [DOI] [PubMed] [Google Scholar]
  16. Cassens G, Wolfe L, Zola M. The neuropsychology of depressions. Journal of Neuropsychiatry and Clinical Neurosciences. 1990;2:202–213. doi: 10.1176/jnp.2.2.202. [DOI] [PubMed] [Google Scholar]
  17. Castellon SA, Hardy DJ, Hinkin CH, Satz P, Stenquist PK, van Gorp WG, et al. Components of depression in HIV-1 infection: Their differential relationship to neurocognitive performance. Journal of Clinical and Experimental Neuropsychology. 2006;28(3):420–437. doi: 10.1080/13803390590935444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Chelune GJ, Heaton RK, Lehman RAW. Neuropsychological and personality correlates of patients’ complaints of disability. In: Goldstein G, Tarter RE, editors. Advances in clinical neuropsychology. Vol. 3. New York: Plenum Press; 1986. pp. 95–126. [Google Scholar]
  19. Ciesla JA, Roberts JE. A meta-analysis of risk for Major Depressive Disorder among HIV-positive individuals. American Journal of Psychiatry. 2001;158:725–730. doi: 10.1176/appi.ajp.158.5.725. [DOI] [PubMed] [Google Scholar]
  20. Conners CK MHS Staff. Conners’ Continuous Performance Test II (CPT II V.5) North Tonawanda, NY: Multi-Health Systems Inc.; 2000. [Google Scholar]
  21. Cummings JL, Mega M, Gray JK, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–2314. doi: 10.1212/wnl.44.12.2308. [DOI] [PubMed] [Google Scholar]
  22. Cysique LA, Deutsch R, Atkinson JH, Young C, Marcotte TD, Dawson L, et al. Incident major depression does not affect neuropsychological functioning in HIV-infected men. Journal of International Neuropsychological Society. 2007;13(1):1–11. doi: 10.1017/S1355617707070026. [DOI] [PubMed] [Google Scholar]
  23. Diehr MC, Cherner M, Wolfson T, Miller SW, Grant I, Heaton RK, et al. The 50 and 100-item short forms of the Paced Auditory Serial Addition Task (PASAT): Demographically corrected norms and comparisons with the full PASAT in normal and clinical samples. Journal of Clinical and Experimental Neuropsychology. 2003;25:571–585. doi: 10.1076/jcen.25.4.571.13876. [DOI] [PubMed] [Google Scholar]
  24. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV Axis I disorders — patient edition (SCID I/P, version 2.0 ed.) New York: Biometrics Research Department; 1995. [Google Scholar]
  25. Goggin KJ, Zisook S, Heaton RK, Atkinson JH, Marshall S, McCutchan JA, et al. Neuropsychological performance in HIV-1 infected men with major depression. Journal of the International Neuropsychological Society. 1997;3:457–464. [PubMed] [Google Scholar]
  26. Golden CJ. Stroop color and word test. Wood Dale, IL: Stoelting Co.; 1978. [Google Scholar]
  27. Grant I, Olshen RA, Atkinson JH, Heaton RK, Nelson J, McCutchan JA, et al. Depressed mood does not explain neuropsychological deficits in HIV-infected persons. Neuropsychology. 1993;7:53–61. [Google Scholar]
  28. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. Journal of Infectious Diseases. 2005;191:339–347. doi: 10.1086/427192. [DOI] [PubMed] [Google Scholar]
  29. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999;13(9):1099–1107. doi: 10.1097/00002030-199906180-00014. [DOI] [PubMed] [Google Scholar]
  30. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G. Wisconsin Card Sorting Test manual: Revised and expanded. Odessa, FL: Psychological Assessment Resources; 1993. [Google Scholar]
  31. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. Journal of the International Neuropsychological Society. 2004a;10:317–331. doi: 10.1017/S1355617704102130. [DOI] [PubMed] [Google Scholar]
  32. Heaton RK, Miller W, Taylor MJ, Grant I. Revised comprehensive norms for an Expanded Halstead-Reitan Battery: Demographically adjusted neuropsychological norms for African American and Caucasian adults. Lutz, FL: Psychological Assessment Resources; 2004b. [Google Scholar]
  33. Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI, et al. Medication adherence among HIV+ adults: The effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59(12):1944–1950. doi: 10.1212/01.wnl.0000038347.48137.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Hinkin CH, Castellon SA, Van Gorp WG, Satz P. Neuropsychological features of HIV disease. In: Van Gorp WG, Buckingham SL, editors. Practitioner’s guide to the neuropsychiatry of HIV/AIDS. New York, NY: Guilford Press; 1998. pp. 1–41. [Google Scholar]
  35. Hinkin CH, Van Gorp WG, Satz P, Marcotte T, Durvasula RS, Wood S, et al. Actual versus self-reported cognitive dysfunction in HIV-1 infection: Memory–metamemory dissociations. Journal of Clinical Experimental Neuropsychology. 1996;18(3):431–443. doi: 10.1080/01688639608408999. [DOI] [PubMed] [Google Scholar]
  36. Hinkin CH, Van Gorp WG, Satz P, Weisman JD, Thommes J, Buckingham S, et al. Depressed mood and its relationship to neuropsychological test performance in HIV-1 seropositive individuals. Journal of Clinical and Experimental Neuropsychology. 1992;14:289–297. doi: 10.1080/01688639208402829. [DOI] [PubMed] [Google Scholar]
  37. Hoth KF, Paulsen JS, Moser DJ, Tranel D, Clark LA, Bechara A. Patients with Huntington’s disease have impaired awareness of cognitive, emotional, and functional abilities. Journal of Clinical and Experimental Neuropsychology. 2007;29(4):365–376. doi: 10.1080/13803390600718958. [DOI] [PubMed] [Google Scholar]
  38. Huberty CJ. Applied discriminant analysis. New York: John Wiley & Sons, Inc.; 1994. [Google Scholar]
  39. Levine AJ, Hinkin CH, Marion S, Keuning A, Castellon SA, Lam MN, et al. Adherence to antiretroviral medications in HIV: Differences in data collected via self-report and electronic monitoring. Health Psychology. 2006;25:329–335. doi: 10.1037/0278-6133.25.3.329. [DOI] [PubMed] [Google Scholar]
  40. Lima VD, Geller J, Bangsberg DR, Patterson TL, Daniel M, Kerr T, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS. 2007;21(9):1175–1183. doi: 10.1097/QAD.0b013e32811ebf57. [DOI] [PubMed] [Google Scholar]
  41. Mapou RL, Law WA, Martin A, Kampen D, Salazar AM, Rundell JR. Neuropsychological performance, mood, and complaints of cognitive and motor difficulties in individuals infected with the human immunodeficiency virus. Journal of Neuropsychiatry and Clinical Neurosciences. 1993;5:86–93. doi: 10.1176/jnp.5.1.86. [DOI] [PubMed] [Google Scholar]
  42. Marcotte TD, Heaton RK, Wolfson T, Taylor MJ, Alhassoon O, Arfaa K, et al. The impact of HIV-related neuropsychological dysfunction on driving behavior. Journal of the International Neuropsychological Society. 1999;5:579–592. doi: 10.1017/s1355617799577011. [DOI] [PubMed] [Google Scholar]
  43. Marcotte TD, Lazzaretto D, Scott JC, Roberts E, Woods SP, Letendre S, et al. Visual attention deficits are associated with driving accidents in cognitively-impaired HIV-infected individuals. Journal of Clinical and Experimental Neuropsychology. 2006;28:13–28. doi: 10.1080/13803390490918048. [DOI] [PubMed] [Google Scholar]
  44. Marcotte TD, Wolfson MA, Rosenthal ME, Heaton RK, Gonzalez MA, Ellis RJ. A multimodal assessment of driving performance in HIV infection. Neurology. 2004;63:1417–1422. doi: 10.1212/01.wnl.0000141920.33580.5d. [DOI] [PubMed] [Google Scholar]
  45. Mason KI, Campbell A, Hawkins P, Madhere S, Johnson K, Takushi-Chinen R. Neuropsychological functioning in HIV-positive African-American women with a -istory of drug use. Journal of the National Medical Association. 1998;90:665–674. [PMC free article] [PubMed] [Google Scholar]
  46. Millikin CP, Rourke SB, Halman MH, Power C. Fatigue in HIV/AIDS is associated with depression and subjective neurocognitive complaints but not neuropsychological functioning. Journal of Clinical and Experimental Neuropsychology. 2003;25(2):201–215. doi: 10.1076/jcen.25.2.201.13644. [DOI] [PubMed] [Google Scholar]
  47. Moore LH, van Gorp WG, Hinkin CH, Stern MJ, Swales T, Satz P. Subjective complaints versus actual cognitive deficits in predominantly symptomatic HIV-1 seropositive individuals. Journal of Neuropsychiatry Clinical Neuroscience. 1997;9(1):37–44. doi: 10.1176/jnp.9.1.37. [DOI] [PubMed] [Google Scholar]
  48. Okonkwo MA, Griffith H, Vance DE, Marson DC, Ball K, Wadley VG. Awareness of functional difficulties in Mild Cognitive Impairment: A multidomain assessment approach. Journal of the American Geriatrics Society. 2009;57(6):978–984. doi: 10.1111/j.1532-5415.2009.02261.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, Langa KM. Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: The aging, demographics, and memory study. Journal of the American Geriatric Society. 2010;58(2):330–337. doi: 10.1111/j.1532-5415.2009.02680.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine. 2000;133(1):21–30. doi: 10.7326/0003-4819-133-1-200007040-00004. [DOI] [PubMed] [Google Scholar]
  51. Perno CF, Ceccherini-Silberstein F, De Luca A, Cozzi-Lepri A, Gori C, Cingolani A, et al. Virologic correlates of adherence to antiretroviral medications and therapeutic failure. Journal of Acquired Immune Deficiency Syndrome. 2002;31(3):S118–S122. doi: 10.1097/00126334-200212153-00006. [DOI] [PubMed] [Google Scholar]
  52. Rabkin JG, Goetz RR, Remien RH, Williams J, Todak G, Gorman J. Stability of mood despite HIV illness progression in a group of homosexual men. American Journal of Psychiatry. 1997;154(2):231–238. doi: 10.1176/ajp.154.2.231. [DOI] [PubMed] [Google Scholar]
  53. Ragland DR, Satariano WA, MacLeod KE. Driving cessation and increased depressive symptoms. The Journals of Gerontology: Series A: Biological Sciences and Medical Sciences. 2005;60(3):399–403. doi: 10.1093/gerona/60.3.399. [DOI] [PubMed] [Google Scholar]
  54. Roberts JL, Clare L, Woods RT. Subjective memory complaints and awareness of memory functioning in mild cognitive impairment: A systematic review. Dementia and Geriatric Cognitive Disorders. 2009;28(2):95–109. doi: 10.1159/000234911. [DOI] [PubMed] [Google Scholar]
  55. Rosen HJ, Alcantar O, Rothlind J, Sturm V, Kramer JH, Weiner M, et al. Neuroanatomical correlates of cognitive self-appraisal in neurodegenerative disease. Neuroimage. 2009;49(4):3358–3364. doi: 10.1016/j.neuroimage.2009.11.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Rosenthal TJ, Parseghian Z, Allen RW, Stein AC. STISIM: The low cost driving simulator. Hawthorne, CA: Systems Technology, Inc.; 1995. [Google Scholar]
  57. Rourke SB, Halman MH, Bassel C. Neurocognitive complaints in HIV-infection and their relationship to depressive symptoms and neuropsychological functioning. Journal of Clinical and Experimental Neuropsychology. 1999a;21(6):737–756. doi: 10.1076/jcen.21.6.737.863. [DOI] [PubMed] [Google Scholar]
  58. Rourke SB, Halman MH, Bassel C. Neuropsychiatric correlates of metamemory dissociations in HIV infection. Journal of Clinical and Experimental Neuropsychology. 1999b;21(6):757–768. doi: 10.1076/jcen.21.6.757.852. [DOI] [PubMed] [Google Scholar]
  59. Sadek JR, Vigil O, Grant I, Heaton RK HNRC Group. The impact of neuropsychological functioning and depressed mood on functional complaints in HIV-1 infection and methamphetamine dependence. Journal of Clinical and Experimental Neuropsychology. 2007;29(3):266–276. doi: 10.1080/13803390600659384. [DOI] [PubMed] [Google Scholar]
  60. Salmon E, Perani D, Herholz K, Marique P, Kalbe E, Holthoff V, et al. Neural correlates of anosognosia for cognitive impairment in Alzheimer’s disease. Human Brain Mapping. 2006;27(7):588–597. doi: 10.1002/hbm.20203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Satz P, Myers HF, Maj M, Fawzy F, Forney DL, Bing EG, et al. Depression, substance use, and sexual orientation as co-factors in HIV-1 infected men: Cross-cultural comparisons. In: Onkin LS, Blaine JD, Genzer S, Horton AM, editors. NIDA Research Monograph. Rockville, MD: National Institute on Drug Abuse; 1997. [PubMed] [Google Scholar]
  62. Simoni JM, Frick PA, Huang B. A longitudinal evaluation of a social support model of medication adherence among HIV positive men and women on antiretroviral therapy. Health Psychology. 2006;25(1):74–81. doi: 10.1037/0278-6133.25.1.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8(3):261–269. doi: 10.1080/09540129650125696. [DOI] [PubMed] [Google Scholar]
  64. Smith CA, Henderson VW, McCleary CA, Murdock GA, Buckwalter JG. Anosognosia and Alzheimer’s disease: The role of depressive symptoms in mediating impaired insight. Journal of Clinical and Experimental Neuropsychology. 2000;22:437–444. doi: 10.1076/1380-3395(200008)22:4;1-0;FT437. [DOI] [PubMed] [Google Scholar]
  65. Snowden JS, Neary D, Mann DA. Frontotemporal dementia. British Journal of Psychiatry. 2002;180:140–143. doi: 10.1192/bjp.180.2.140. [DOI] [PubMed] [Google Scholar]
  66. Starkstein SE, Sabe L, Chemerinski E, Jason L, Leiguarda R. Two domains of anosognosia in Alzheimer’s disease. Journal of Neurology, Neurosurgery, and Psychiatry. 1996;61:485–490. doi: 10.1136/jnnp.61.5.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Taylor MJ, Heaton RK. Sensitivity and specificity of WAIS-III/WMS-III demographically corrected factors scores in neuropsychological assessment. Journal of the International Neuropsychological Society. 2001;7:867–874. [PubMed] [Google Scholar]
  68. Van Gorp WG, Satz P, Hinkin C, Selnes O, Miller EN, McArthur J, et al. Metacognition in HIV-1 seropositive asymptomatic individuals: Self-ratings versus objective neuropsychological performance. Multicenter AIDS Cohort Study (MACS) Journal of Clinical and Experimental Neuropsychology. 1991;13(5):812–819. doi: 10.1080/01688639108401091. [DOI] [PubMed] [Google Scholar]
  69. von Giesen HJ, Baecker R, Hefter H, Arendt G. Depression does not influence basal ganglia-mediated psychomotor speed in HIV-1 infection. Journal of Neuropsychiatry & Clinical Neurosciences. 2001;13:88–94. doi: 10.1176/jnp.13.1.88. [DOI] [PubMed] [Google Scholar]
  70. Wechsler D. WAIS-III administration and scoring manual. San Antonio, TX: Psychological Corporation; 1997. [Google Scholar]
  71. Wilkins JW, Robertson KR, Snyder CR, Robertson WK, van der Horst C, Hall CD. Implications of self-reported cognitive and motor dysfunction in HIV-positive patients. American Journal of Psychiatry. 1991;148:641–643. doi: 10.1176/ajp.148.5.641. [DOI] [PubMed] [Google Scholar]
  72. Windsor TD, Anstey KJ, Butterworth P, Luszcz MA, Andrews GR. The role of perceived control in explaining depressive symptoms associated with driving cessation in a longitudinal study. Gerontologist. 2007;47(2):215–223. doi: 10.1093/geront/47.2.215. [DOI] [PubMed] [Google Scholar]
  73. Woods SP, Moore DJ, Weber L, Grant I. Cognitive neuropsychology of HIV-1 associated neurocognitive disorder. Neuropsychology Review. 2009;19(2):152–168. doi: 10.1007/s11065-009-9102-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES